S1675 Tirzepatide vs Semaglutide in Obese Patients With MAFLD or MASH: A Comparative Analysis of Cardiovascular and Gastrointestinal Outcomes, and the Risk of Progression to Fibrosis or Hepatocellular Carcinoma | Publicación